In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

A rituximab biosimilar has been approved by the FDA.

Antibodies directed against TNFR2, a regulator in the TME that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.

The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.

Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.

Shorter treatments of venetoclax plus azacitidine did not meet similarity criteria for longer treatments in the OPTI-AML trial.

The FDA has granted orphan drug designation to enzomenib for acute lymphoblastic leukemia.

FDA has granted RMAT and fast track designations to cema-cel as a frontline consolidation in large B-cell lymphoma.